25 XP   0   0   10

Geneuro SA
Buy, Hold or Sell?

Let's analyse Geneuro together

PenkeI guess you are interested in Geneuro SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Geneuro SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Geneuro SA

I send you an email if I find something interesting about Geneuro SA.

Quick analysis of Geneuro (30 sec.)










What can you expect buying and holding a share of Geneuro? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-0.19
Expected worth in 1 year
€-0.78
How sure are you?
25.6%

+ What do you gain per year?

Total Gains per Share
€-0.59
Return On Investment
-41.5%

For what price can you sell your share?

Current Price per Share
€1.43
Expected price per share
€1.4 - €1.53
How sure are you?
50%

1. Valuation of Geneuro (5 min.)




Live pricePrice per Share (EOD)

€1.43

Intrinsic Value Per Share

€-8.03 - €-4.36

Total Value Per Share

€-8.22 - €-4.55

2. Growth of Geneuro (5 min.)




Is Geneuro growing?

Current yearPrevious yearGrowGrow %
How rich?-$5.9m$5.1m-$6.1m-625.7%

How much money is Geneuro making?

Current yearPrevious yearGrowGrow %
Making money-$5.9m-$3.6m-$2.3m-39.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Geneuro (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#822 / 1010

Most Revenue
#950 / 1010

Most Profit
#607 / 1010

Most Efficient
#385 / 1010

What can you expect buying and holding a share of Geneuro? (5 min.)

Welcome investor! Geneuro's management wants to use your money to grow the business. In return you get a share of Geneuro.

What can you expect buying and holding a share of Geneuro?

First you should know what it really means to hold a share of Geneuro. And how you can make/lose money.

Speculation

The Price per Share of Geneuro is €1.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Geneuro.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Geneuro, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-0.19. Based on the TTM, the Book Value Change Per Share is €-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is €0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Geneuro.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.12-8.7%-0.12-8.7%-0.08-5.7%-0.09-6.6%-0.07-5.1%
Usd Book Value Change Per Share-0.25-17.7%-0.16-11.1%0.053.3%-0.03-2.2%-0.01-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.25-17.7%-0.16-11.1%0.053.3%-0.03-2.2%-0.01-0.4%
Usd Price Per Share1.77-1.94-3.37-3.45-3.55-
Price to Earnings Ratio-3.56--3.92--11.31--10.21--7.63-
Price-to-Total Gains Ratio-6.97--7.08-34.15--6.97-98,857.49-
Price to Book Ratio-8.73-23.61-24.09-32.92-19.83-
Price-to-Total Gains Ratio-6.97--7.08-34.15--6.97-98,857.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.529957
Number of shares653
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.16-0.03
Usd Total Gains Per Share-0.16-0.03
Gains per Quarter (653 shares)-103.70-20.73
Gains per Year (653 shares)-414.81-82.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-415-4250-83-93
20-830-8400-166-176
30-1244-12550-249-259
40-1659-16700-332-342
50-2074-20850-415-425
60-2489-25000-498-508
70-2904-29150-580-591
80-3318-33300-663-674
90-3733-37450-746-757
100-4148-41600-829-840

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%0.011.00.00.0%0.019.00.00.0%6.033.00.015.4%6.036.00.014.3%
Book Value Change Per Share0.02.01.00.0%2.04.05.018.2%3.07.09.015.8%10.014.015.025.6%10.015.017.023.8%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.039.00.0%0.00.042.00.0%
Total Gains per Share0.02.01.00.0%2.04.05.018.2%3.07.09.015.8%10.014.015.025.6%10.015.017.023.8%

Fundamentals of Geneuro

About Geneuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Fundamental data was last updated by Penke on 2024-04-09 14:28:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Geneuro SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Geneuro earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Geneuro to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Geneuro SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-500.3%+500.3%
5Y-500.3%10Y-721.5%+221.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--218.5%+218.5%
YOY--284.8%+284.8%
5Y-500.3%-435.1%-65.2%
10Y-721.5%-589.3%-132.2%
1.1.2. Return on Assets

Shows how efficient Geneuro is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Geneuro to the Biotechnology industry mean.
  • -56.2% Return on Assets means that Geneuro generated €-0.56 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Geneuro SA:

  • The MRQ is -56.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -47.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-56.2%TTM-47.8%-8.4%
TTM-47.8%YOY-27.2%-20.6%
TTM-47.8%5Y-30.3%-17.5%
5Y-30.3%10Y-17.5%-12.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.2%-13.2%-43.0%
TTM-47.8%-12.7%-35.1%
YOY-27.2%-11.5%-15.7%
5Y-30.3%-13.8%-16.5%
10Y-17.5%-15.5%-2.0%
1.1.3. Return on Equity

Shows how efficient Geneuro is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Geneuro to the Biotechnology industry mean.
  • 0.0% Return on Equity means Geneuro generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Geneuro SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-234.8%+234.8%
TTM-234.8%YOY-70.0%-164.8%
TTM-234.8%5Y-124.6%-110.2%
5Y-124.6%10Y-71.3%-53.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.8%+16.8%
TTM-234.8%-16.0%-218.8%
YOY-70.0%-14.8%-55.2%
5Y-124.6%-19.3%-105.3%
10Y-71.3%-20.0%-51.3%

1.2. Operating Efficiency of Geneuro SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Geneuro is operating .

  • Measures how much profit Geneuro makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Geneuro to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Geneuro SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-465.0%+465.0%
5Y-465.0%10Y-692.3%+227.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.8%+299.8%
TTM--239.2%+239.2%
YOY--295.4%+295.4%
5Y-465.0%-485.9%+20.9%
10Y-692.3%-624.6%-67.7%
1.2.2. Operating Ratio

Measures how efficient Geneuro is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Geneuro SA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y2.647-2.647
5Y2.64710Y1.435+1.212
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.238-3.238
TTM-3.313-3.313
YOY-3.838-3.838
5Y2.6475.675-3.028
10Y1.4357.612-6.177

1.3. Liquidity of Geneuro SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Geneuro is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.08 means the company has €2.08 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Geneuro SA:

  • The MRQ is 2.081. The company is able to pay all its short-term debts. +1
  • The TTM is 2.303. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.081TTM2.303-0.222
TTM2.303YOY2.473-0.170
TTM2.3035Y2.338-0.035
5Y2.33810Y1.766+0.572
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0813.870-1.789
TTM2.3034.173-1.870
YOY2.4735.332-2.859
5Y2.3386.126-3.788
10Y1.7666.448-4.682
1.3.2. Quick Ratio

Measures if Geneuro is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Geneuro to the Biotechnology industry mean.
  • A Quick Ratio of 1.85 means the company can pay off €1.85 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Geneuro SA:

  • The MRQ is 1.847. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.423. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.847TTM1.423+0.424
TTM1.423YOY1.436-0.013
TTM1.4235Y1.216+0.208
5Y1.21610Y0.678+0.538
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8473.510-1.663
TTM1.4233.994-2.571
YOY1.4365.357-3.921
5Y1.2166.105-4.889
10Y0.6786.404-5.726

1.4. Solvency of Geneuro SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Geneuro assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Geneuro to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.46 means that Geneuro assets are financed with 145.8% credit (debt) and the remaining percentage (100% - 145.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Geneuro SA:

  • The MRQ is 1.458. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.070. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.458TTM1.070+0.388
TTM1.070YOY0.613+0.458
TTM1.0705Y0.797+0.273
5Y0.79710Y0.659+0.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4580.339+1.119
TTM1.0700.336+0.734
YOY0.6130.271+0.342
5Y0.7970.368+0.429
10Y0.6590.388+0.271
1.4.2. Debt to Equity Ratio

Measures if Geneuro is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Geneuro to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Geneuro SA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.720-4.720
TTM4.720YOY1.636+3.084
TTM4.7205Y4.374+0.347
5Y4.37410Y3.098+1.276
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.390-0.390
TTM4.7200.402+4.318
YOY1.6360.339+1.297
5Y4.3740.428+3.946
10Y3.0980.461+2.637

2. Market Valuation of Geneuro SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Geneuro generates.

  • Above 15 is considered overpriced but always compare Geneuro to the Biotechnology industry mean.
  • A PE ratio of -3.56 means the investor is paying €-3.56 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Geneuro SA:

  • The EOD is -3.084. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.558. Based on the earnings, the company is expensive. -2
  • The TTM is -3.918. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.084MRQ-3.558+0.474
MRQ-3.558TTM-3.918+0.359
TTM-3.918YOY-11.305+7.388
TTM-3.9185Y-10.207+6.290
5Y-10.20710Y-7.628-2.579
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.084-2.296-0.788
MRQ-3.558-2.600-0.958
TTM-3.918-2.726-1.192
YOY-11.305-4.145-7.160
5Y-10.207-6.259-3.948
10Y-7.628-6.348-1.280
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Geneuro SA:

  • The EOD is -2.253. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.599. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.613. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.253MRQ-2.599+0.347
MRQ-2.599TTM-3.613+1.014
TTM-3.613YOY-8.175+4.562
TTM-3.6135Y-10.317+6.704
5Y-10.31710Y-9.162-1.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.253-2.937+0.684
MRQ-2.599-3.326+0.727
TTM-3.613-3.553-0.060
YOY-8.175-5.605-2.570
5Y-10.317-8.385-1.932
10Y-9.162-8.882-0.280
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Geneuro is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -8.73 means the investor is paying €-8.73 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Geneuro SA:

  • The EOD is -7.569. Based on the equity, the company is expensive. -2
  • The MRQ is -8.733. Based on the equity, the company is expensive. -2
  • The TTM is 23.614. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.569MRQ-8.733+1.164
MRQ-8.733TTM23.614-32.348
TTM23.614YOY24.090-0.475
TTM23.6145Y32.919-9.305
5Y32.91910Y19.826+13.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.5691.909-9.478
MRQ-8.7332.114-10.847
TTM23.6142.096+21.518
YOY24.0902.884+21.206
5Y32.9193.554+29.365
10Y19.8263.938+15.888
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Geneuro SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.237-0.148-37%0.044-634%-0.030-87%-0.005-98%
Book Value Per Share---0.189-0.031-84%0.164-215%0.089-311%0.209-190%
Current Ratio--2.0812.303-10%2.473-16%2.338-11%1.766+18%
Debt To Asset Ratio--1.4581.070+36%0.613+138%0.797+83%0.659+121%
Debt To Equity Ratio---4.720-100%1.636-100%4.374-100%3.098-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.116-0.1160%-0.077-34%-0.088-24%-0.069-41%
Free Cash Flow Per Share---0.159-0.199+25%-0.081-49%-0.096-40%-0.061-61%
Free Cash Flow To Equity Per Share--0.065-0.029+144%0.102-36%-0.009+114%0.084-22%
Gross Profit Margin--1.2461.168+7%1.146+9%1.057+18%1.028+21%
Intrinsic Value_10Y_max---4.360--------
Intrinsic Value_10Y_min---8.028--------
Intrinsic Value_1Y_max---0.274--------
Intrinsic Value_1Y_min---0.498--------
Intrinsic Value_3Y_max---0.947--------
Intrinsic Value_3Y_min---1.771--------
Intrinsic Value_5Y_max---1.770--------
Intrinsic Value_5Y_min---3.335--------
Market Cap42322566.000-15%48833730.00053766430.000-9%93302020.500-48%95471110.421-49%98259384.000-50%
Net Profit Margin----0%-0%-5.0030%-7.2150%
Operating Margin----0%-0%-4.6500%-6.9230%
Operating Ratio----0%-0%2.647-100%1.435-100%
Pb Ratio-7.569+13%-8.73323.614-137%24.090-136%32.919-127%19.826-144%
Pe Ratio-3.084+13%-3.558-3.918+10%-11.305+218%-10.207+187%-7.628+114%
Price Per Share1.430-15%1.6501.817-9%3.153-48%3.226-49%3.320-50%
Price To Free Cash Flow Ratio-2.253+13%-2.599-3.613+39%-8.175+215%-10.317+297%-9.162+253%
Price To Total Gains Ratio-6.042+13%-6.971-7.081+2%34.149-120%-6.971+0%98857.495-100%
Quick Ratio--1.8471.423+30%1.436+29%1.216+52%0.678+172%
Return On Assets---0.562-0.478-15%-0.272-52%-0.303-46%-0.175-69%
Return On Equity----2.3480%-0.7000%-1.2460%-0.7130%
Total Gains Per Share---0.237-0.148-37%0.044-634%-0.030-87%-0.005-98%
Usd Book Value---5982666.820-986162.493-84%5184681.638-215%2832548.932-311%6628699.846-190%
Usd Book Value Change Per Share---0.253-0.159-37%0.047-634%-0.032-87%-0.005-98%
Usd Book Value Per Share---0.202-0.033-84%0.175-215%0.096-311%0.224-190%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.124-0.1240%-0.082-34%-0.095-24%-0.074-41%
Usd Free Cash Flow---5025320.300-6294507.007+25%-1913663.261-62%-2876635.907-43%-1896169.368-62%
Usd Free Cash Flow Per Share---0.170-0.213+25%-0.086-49%-0.103-40%-0.066-61%
Usd Free Cash Flow To Equity Per Share--0.070-0.031+144%0.109-36%-0.010+114%0.089-22%
Usd Market Cap45280913.363-15%52247207.72757524703.457-9%99823831.733-48%102144541.039-49%105127714.942-50%
Usd Price Per Share1.530-15%1.7651.944-9%3.373-48%3.451-49%3.552-50%
Usd Profit---7341760.790-5997698.915-18%-3647088.494-50%-3767769.694-49%-2586118.387-65%
Usd Revenue----0%-0%6481.342-100%1050837.263-100%
Usd Total Gains Per Share---0.253-0.159-37%0.047-634%-0.032-87%-0.005-98%
 EOD+2 -6MRQTTM+11 -16YOY+5 -245Y+9 -2210Y+7 -24

3.2. Fundamental Score

Let's check the fundamental score of Geneuro SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.084
Price to Book Ratio (EOD)Between0-1-7.569
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.847
Current Ratio (MRQ)Greater than12.081
Debt to Asset Ratio (MRQ)Less than11.458
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.562
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Geneuro SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.146
Ma 20Greater thanMa 501.446
Ma 50Greater thanMa 1001.310
Ma 100Greater thanMa 2001.233
OpenGreater thanClose1.430
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets12,208
Total Liabilities17,800
Total Stockholder Equity-5,592
 As reported
Total Liabilities 17,800
Total Stockholder Equity+ -5,592
Total Assets = 12,208

Assets

Total Assets12,208
Total Current Assets9,709
Long-term Assets2,499
Total Current Assets
Cash And Cash Equivalents 7,398
Short-term Investments -210
Net Receivables 1,430
Other Current Assets 881
Total Current Assets  (as reported)9,709
Total Current Assets  (calculated)9,500
+/- 210
Long-term Assets
Property Plant Equipment 888
Intangible Assets 1,140
Long-term Assets Other 201
Long-term Assets  (as reported)2,499
Long-term Assets  (calculated)2,229
+/- 270

Liabilities & Shareholders' Equity

Total Current Liabilities4,666
Long-term Liabilities13,134
Total Stockholder Equity-5,592
Total Current Liabilities
Short-term Debt 658
Short Long Term Debt 374
Accounts payable 2
Other Current Liabilities 4,007
Total Current Liabilities  (as reported)4,666
Total Current Liabilities  (calculated)5,041
+/- 375
Long-term Liabilities
Long term Debt Total 6,126
Long term Debt 5,510
Capital Lease Obligations 901
Other Liabilities 472
Long-term Liabilities Other 35
Long-term Liabilities  (as reported)13,134
Long-term Liabilities  (calculated)13,045
+/- 90
Total Stockholder Equity
Common Stock1,100
Retained Earnings -49,184
Accumulated Other Comprehensive Income 42,518
Capital Surplus 34
Other Stockholders Equity -27
Total Stockholder Equity (as reported)-5,592
Total Stockholder Equity (calculated)-5,558
+/- 34
Other
Capital Stock1,100
Cash And Equivalents7,398
Cash and Short Term Investments 7,398
Common Stock Shares Outstanding 24,852
Current Deferred Revenue-2
Liabilities and Stockholders Equity 12,208
Net Debt 220
Net Invested Capital 6,352
Net Tangible Assets -6,671
Net Working Capital 5,044
Property Plant and Equipment Gross 2,524
Short Long Term Debt Total 7,619



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-06-302023-03-312022-12-312022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
5,131
0
0
0
4,196
0
0
9,056
9,056
7,535
7,535
20,764
20,764
44,377
44,377
37,781
37,781
27,871
27,871
30,370
30,370
21,958
21,958
14,052
14,052
14,229
14,229
0
9,399
0
13,158
0
10,511
0
7,444
0
12,421
0
16,019
11,420
0
12,208
12,208011,42016,019012,42107,444010,511013,15809,399014,22914,22914,05214,05221,95821,95830,37030,37027,87127,87137,78137,78144,37744,37720,76420,7647,5357,5359,0569,056004,1960005,131
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
20,546
0
43,850
35,935
35,935
26,069
26,069
28,587
28,587
19,981
19,981
12,448
12,448
11,690
11,690
7,281
7,281
11,226
11,226
7,663
7,663
4,638
4,638
9,870
9,870
0
12,617
9,088
9,709
9,709
9,7099,7099,08812,61709,8709,8704,6384,6387,6637,66311,22611,2267,2817,28111,69011,69012,44812,44819,98119,98128,58728,58726,06926,06935,93535,93543,850020,546000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
18,557
0
41,399
34,489
34,489
23,097
23,097
26,602
26,602
17,315
17,315
8,961
8,961
9,992
9,992
0
5,931
0
10,492
0
6,843
0
2,961
0
5,480
0
10,999
5,593
0
7,398
7,39805,59310,99905,48002,96106,843010,49205,93109,9929,9928,9618,96117,31517,31526,60226,60223,09723,09734,48934,48941,399018,557000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
1,003
0
0
0
0
0
0
0
0
0
0
34
34
0
0
0
0
0
0
0
0
0
0
0
0
0
-687
0
0
-210
-21000-6870000000000000343400000000001,003000000000000
       Net Receivables 
835
0
0
0
712
0
0
990
990
301
301
750
750
1,101
1,101
524
524
1,480
1,480
1,201
1,201
1,939
1,939
2,626
2,626
820
820
975
975
275
275
609
609
1,177
1,177
1,167
1,233
0
1,276
1,482
1,328
1,430
1,4301,3281,4821,27601,2331,1671,1771,1776096092752759759758208202,6262,6261,9391,9391,2011,2011,4801,4805245241,1011,10175075030130199099000712000835
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
166
0
135
1,397
0
424
42401,3971350166000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
218
0
527
0
1,846
0
1,802
0
1,783
0
1,977
0
1,604
0
2,539
0
2,118
0
1,932
0
2,848
0
2,806
0
2,551
0
3,402
2,332
0
2,499
2,49902,3323,40202,55102,80602,84801,93202,11802,53901,60401,97701,78301,80201,84605270218000000000000
       Property Plant Equipment 
119
0
0
0
77
0
0
38
38
29
29
67
67
67
67
154
154
151
151
125
125
117
117
101
101
813
813
678
678
507
507
1,442
1,442
1,334
1,334
1,218
1,218
0
1,097
993
888
888
8888889931,09701,2181,2181,3341,3341,4421,44250750767867881381310110111711712512515115115415467676767292938380077000119
       Intangible Assets 
126
0
0
0
122
0
0
125
125
152
152
145
145
143
143
1,101
1,101
1,130
1,130
1,131
1,131
1,125
1,125
1,163
1,163
1,159
1,159
0
1,155
0
1,153
0
1,149
0
1,148
0
1,142
0
1,140
1,140
0
1,140
1,14001,1401,14001,14201,14801,14901,15301,15501,1591,1591,1631,1631,1251,1251,1311,1311,1301,1301,1011,10114314314514515215212512500122000126
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
306
0
591
0
522
0
527
0
735
0
340
0
567
0
286
0
1,425
0
257
0
324
0
190
0
197
199
0
201
201019919701900324025701,4250286056703400735052705220591030600000000000000
> Total Liabilities 
5,193
0
0
0
1,487
0
0
2,816
2,816
2,990
2,990
19,069
19,069
18,722
18,722
19,113
19,113
17,192
17,192
17,313
17,313
10,865
10,865
8,497
8,497
13,227
13,227
0
14,608
0
4,852
0
4,996
0
5,100
0
7,695
0
8,432
10,007
0
17,800
17,800010,0078,43207,69505,10004,99604,852014,608013,22713,2278,4978,49710,86510,86517,31317,31317,19217,19219,11319,11318,72218,72219,06919,0692,9902,9902,8162,816001,4870005,193
   > Total Current Liabilities 
4,700
0
0
0
1,029
0
0
2,065
2,065
2,059
2,059
8,355
8,355
9,343
9,343
12,555
12,555
15,557
15,557
15,520
15,520
8,811
8,811
6,383
6,383
10,642
10,642
10,982
10,982
2,227
2,227
2,328
2,328
2,632
2,632
3,069
3,069
0
3,646
3,309
4,666
4,666
4,6664,6663,3093,64603,0693,0692,6322,6322,3282,3282,2272,22710,98210,98210,64210,6426,3836,3838,8118,81115,52015,52015,55715,55712,55512,5559,3439,3438,3558,3552,0592,0592,0652,065001,0290004,700
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,003
0
0
183
183
215
215
182
182
184
184
0
0
7
7,824
0
8,026
0
353
0
244
0
239
0
257
0
590
602
0
658
6580602590025702390244035308,02607,824700184184182182215215183183001,003000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
183
183
215
215
182
182
184
184
0
0
7
7,500
0
7,689
0
16
0
49
0
69
0
0
0
323
328
0
374
37403283230006904901607,68907,500700184184182182215215183183000000000000000
       Accounts payable 
731
0
0
0
411
0
0
1,034
1,034
1,511
1,511
1,885
1,885
4,655
4,655
3,032
3,032
3,852
3,852
3,474
3,474
5,448
5,448
5,435
5,435
1,931
1,931
1,247
1,247
596
596
540
540
913
913
581
1
0
1,579
1
1,818
2
21,81811,579015819139135405405965961,2471,2471,9311,9315,4355,4355,4485,4483,4743,4743,8523,8523,0323,0324,6554,6551,8851,8851,5111,5111,0341,03400411000731
       Other Current Liabilities 
282
0
0
0
306
0
0
1,031
1,031
548
548
6,470
6,470
4,681
4,681
9,502
9,502
11,706
11,706
12,046
12,046
2,564
2,564
47
47
176
12
810
1,710
6
1,278
9
1,543
15
84
497
2,706
0
1,476
2,707
99
4,007
4,007992,7071,47602,70649784151,54391,27861,7108101217647472,5642,56412,04612,04611,70611,7069,5029,5024,6814,6816,4706,4705485481,0311,03100306000282
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
10,715
0
9,380
0
6,557
0
1,635
0
1,793
0
2,054
0
2,114
0
2,585
0
3,626
0
2,625
0
2,669
0
2,468
0
4,625
0
4,785
6,698
0
13,134
13,13406,6984,78504,62502,46802,66902,62503,62602,58502,11402,05401,79301,63506,55709,380010,715000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
451
0
301
0
135
0
1,144
0
1,008
0
3,494
0
4,268
6,379
0
6,126
6,12606,3794,26803,49401,00801,14401350301045100000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
-1,003
0
0
-183
-183
-215
-215
-182
-182
-184
-184
0
0
-7
-7,056
0
-7,396
0
120
0
1,144
0
1,008
0
959
0
536
403
0
243
2430403536095901,00801,14401200-7,3960-7,056-700-184-184-182-182-215-215-183-18300-1,003000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
190
0
181
0
3
0
7
0
2,589
0
156
165
0
35
35016515602,5890703018101900600000000000000000000000000
> Total Stockholder Equity
0
0
0
0
2,709
2,709
0
6,240
6,240
4,545
4,545
1,694
1,694
25,655
25,655
18,668
18,668
10,679
10,679
13,057
13,057
11,093
11,093
5,555
5,555
1,002
1,002
0
-5,209
0
8,306
0
5,515
0
2,344
0
4,727
0
7,587
1,413
0
-5,592
-5,59201,4137,58704,72702,34405,51508,3060-5,20901,0021,0025,5555,55511,09311,09313,05713,05710,67910,67918,66818,66825,65525,6551,6941,6944,5454,5456,2406,24002,7092,7090000
   Retained Earnings -49,184-49,184-69,580-63,1900-58,204-58,204-13,278-13,278-10,022-10,022-6,315-6,315-57,428-57,428-52,486-52,486-47,983-47,983-42,275-42,275-40,182-40,182-42,757-42,757-35,055-35,055-28,2270-21,267000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
-407
0
0
0
-273
0
0
0
-327
0
0
0
-382
0
-556
0
-729
0
-897
0
-931
0
0
0
41,834
0
42,606
42,786
0
42,518
42,518042,78642,606041,834000-9310-8970-7290-5560-382000-327000-273000-407000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
53,706
0
53,649
0
14,702
0
14,702
0
14,702
0
20,244
0
27,156
27,157
0
34
34027,15727,156020,244014,702014,702014,702053,649053,70600000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-289
Gross Profit-289-289
 
Operating Income (+$)
Gross Profit-289
Operating Expense-12,767
Operating Income-13,055-13,055
 
Operating Expense (+$)
Research Development9,675
Selling General Administrative3
Selling And Marketing Expenses3,075
Operating Expense12,76712,754
 
Net Interest Income (+$)
Interest Income8
Interest Expense-269
Other Finance Cost-0
Net Interest Income-262
 
Pretax Income (+$)
Operating Income-13,055
Net Interest Income-262
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-13,514-12,596
EBIT - interestExpense = -13,324
-13,514
-11,931
Interest Expense269
Earnings Before Interest and Taxes (EBIT)-13,055-13,245
Earnings Before Interest and Taxes (EBITDA)-12,767
 
After tax Income (+$)
Income Before Tax-13,514
Tax Provision-2
Net Income From Continuing Ops-12,200-13,516
Net Income-12,200
Net Income Applicable To Common Shares-12,200
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses13,055
Total Other Income/Expenses Net-459262
 

Technical Analysis of Geneuro
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Geneuro. The general trend of Geneuro is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Geneuro's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Geneuro SA.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.49 < 1.53 < 1.53.

The bearish price targets are: 1.425 > 1.4 > 1.4.

Tweet this
Geneuro SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Geneuro SA. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Geneuro SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Geneuro SA. The current macd is 0.03426347.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Geneuro price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Geneuro. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Geneuro price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Geneuro SA Daily Moving Average Convergence/Divergence (MACD) ChartGeneuro SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Geneuro SA. The current adx is 30.39.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Geneuro shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Geneuro SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Geneuro SA. The current sar is 1.51059919.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Geneuro SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Geneuro SA. The current rsi is 58.15. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Geneuro SA Daily Relative Strength Index (RSI) ChartGeneuro SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Geneuro SA. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Geneuro price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Geneuro SA Daily Stochastic Oscillator ChartGeneuro SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Geneuro SA. The current cci is -36.67745415.

Geneuro SA Daily Commodity Channel Index (CCI) ChartGeneuro SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Geneuro SA. The current cmo is 6.5884624.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Geneuro SA Daily Chande Momentum Oscillator (CMO) ChartGeneuro SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Geneuro SA. The current willr is -76.92307692.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Geneuro is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Geneuro SA Daily Williams %R ChartGeneuro SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Geneuro SA.

Geneuro SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Geneuro SA. The current atr is 0.03097249.

Geneuro SA Daily Average True Range (ATR) ChartGeneuro SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Geneuro SA. The current obv is 153,777.

Geneuro SA Daily On-Balance Volume (OBV) ChartGeneuro SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Geneuro SA. The current mfi is 33.91.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Geneuro SA Daily Money Flow Index (MFI) ChartGeneuro SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Geneuro SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Geneuro SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Geneuro SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.146
Ma 20Greater thanMa 501.446
Ma 50Greater thanMa 1001.310
Ma 100Greater thanMa 2001.233
OpenGreater thanClose1.430
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Geneuro with someone you think should read this too:
  • Are you bullish or bearish on Geneuro? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Geneuro? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Geneuro SA

I send you an email if I find something interesting about Geneuro SA.


Comments

How you think about this?

Leave a comment

Stay informed about Geneuro SA.

Receive notifications about Geneuro SA in your mailbox!